Table 3 Results of univariate and multivariable analyses for HMGA2 in the NCRI AML17 validation cohort

From: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia

Outcome

HMGA2 −

HMGA2 +

Unadjusted OR/HR

(95% CI) P

Adjusteda OR/HR

(95% CI) P

n = 160

n = 100

CR and CRib

95.6%

80%

5.05 (2.20–11.6)

 <0.001

3.98 (1.36–11.65)

0.010

Overall survival

51%c

21%c

2.33 (1.61–3.36) <0.001

2.03 (1.36–3.03) <0.001

Relapse-free survival

44%c

21%c

2.13 (1.45–3.13)

 <0.001

2.06 (1.38–3.08)

 <0.001

Cumulative incidence of relapse

46%c

60%c

1.97 (1.28–3.03)

0.002

2.01 (1.28–3.14)

0.002

Cumulative incidence of death

10%c

18%c

2.87 (1.22–6.75)

0.020

2.29 (0.89–5.87)

0.090

Overall survival censored at transplant

60%c

31%c

2.70 (1.68–4.34)

 <0.001

2.00 (1.18–3.39)

0.010

  1. CI confidence intervals, HMGA2− low expression (<1100 NCN), HMGA2+ high expression (≥1100 NCN), HR hazard ratio, OR odds ratio
  2. aVariables included in the multivariable models are: age, log white blood cell count, secondary disease, WHO/ECOG performance status, the presence of adverse cytogenetics, FLT3-ITD, and NPM1 mutations
  3. bComplete remission (CR) and complete remission with incomplete hematologic recovery (CRi) excluding induction deaths
  4. cClinical end-points at 5 years
Back to article page